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Abstract
Background: Processing of Ab-precursor protein (APP) plays an important role in Alzheimer’s Disease (AD) pathogenesis.
Thr residue at amino acid 668 of the APP intracellular domain (AID) is highly conserved. When phosphorylated, this residue
generates a binding site for Pin1. The interaction of APP with Pin1 has been involved in AD pathogenesis.
Methodology/Principal Findings: To dissect the functions of this sequence in vivo, we created an APP knock-in allele, in
which Thr
668 is replaced by an Ala (T
668A). Doubly deficient APP/APP-like protein 2 (APLP2) mice present postnatal lethality
and neuromuscular synapse defects. Previous work has shown that the APP intracellular domain is necessary for preventing
early lethality and neuromuscular junctions (NMJ) defects. Crossing the T
668A allele into the APLP2 knockout background
showed that mutation of Thr
668 does not cause a defective phenotype. Notably, the T
668A mutant APP is able to bind Mint1.
Conclusions/Significance: Our results argue against an important role of the Thr
668 residue in the essential function of APP
in developmental regulation. Furthermore, they indicate that phosphorylation at this residue is not functionally involved in
those APP-mediated functions that prevent (NMJ) defects and early lethality in APLP2 null mice.
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Introduction
Amyloid-b-precursor protein (APP) plays an important role in
Alzheimer’s Disease (AD) pathogenesis [1,2,3,4,5,6,7,8,9,10]. The
prevalent Amyloid cascade hypothesis of AD pathogenesis posits
that dementia is caused by Ab aggregates. The repeated failure of
therapeutic approaches based on this dogma in humans suggests
that alterations of normal APP functions may contribute to AD
pathogenesis. Thus, understanding the role of APP in vivo is much
needed to reveal fundamental insights into AD pathogenesis and
develop potential therapeutic intervention.
APP null mice have given scant information about the functions of
APP and these mice exhibit seizures, impaired grip strength,
locomotor activity, exploratory activity, cognition and LTP [11,12,
13,14,15,16,17,18,19,20,21,22,23,24]. APP Like Protein 1 and 2
(APLP1 and ALPL2), which belong to the APP gene family, are
structurally [25,26] and functionally similar to APP. The evidence
that APLP1
2/2,A P L P 2
2/2,A P P
2/2 and APLP1
2/2APP
2/2 mice
are viable, whereas combined APP
2/2APLP2
2/2 or APLP1
2/2
APLP2
2/2 double KO [27,28] die shortly after birth show that
functional redundancy compensates for the loss of essential gene
functions in APP knock out mice. Analysis of APP/APLP2 double
knockout (dKO) mice uncovered an essential role for the APP
and APLP2 in the patterning of neuromuscular junction (NMJ)
[29,30,31].
Recent evidence shows that the synaptogenic function of APP
requires the highly conserved intracellular domain [32], and in
particular Tyr
682[33]. This residue is part of the YENPTY
sequence (amino acids 682–687, following the numbering of 695
amino acids long brain APP isoform), which is a docking site for
numerous cytosolic proteins [34,35,36,37,38,39,40,41,42,43].
Some proteins, such as Grb2 [44,45], Shc [45,46], Grb7 and
Crk [47] interact with APP only when Tyr
682 is phosphorylated;
others, like Fe65, Fe65L1 and Fe65L2 only when this tyrosine is
not phosphorylated [48].
Thr
668 is another conserved residue of the intracellular region of
APP. This residue has been intensively studied as phosphorylation
of Thr
668 promotes Pin1 binding [49]. The interaction of Pin1
with APP has been shown to reduce APP processing and Ab
generation, thereby protecting from AD [50]. These data are not
easily reconcilable with other evidence showing that mutation of
Thr
668 in vivo does not grossly alter APP processing [51,52]. Here,
we asked whether Thr
668 and its phosphorylation plays an
important physiological role. The NMJ deficits and the early
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animals provide genetic readouts to determine the role of this
amino acid in vivo. We have created an APP knock-in (ki) mouse in
which Thr
668 is replaced by an alanine (we will refer to these mice
as APP
TA), thereby abolishing phosphorylation at this position. We
report that APP
TA/TA/APLP2
2/2 mice, unlike APP/APLP2 double
KO mice, do not present NMJ deficits and early lethality,
demonstrating that phosphorylation of Thr
668 is dispensable for
the essential function of APP in developmental regulation.
Materials and Methods
Mice and Ethics Statement
Mice were maintained on a C57BL/6 background for several
generations (at least 15). Mice were handled according to the
Ethical Guidelines for Treatment of Laboratory Animals of Albert
Einstein College of Medicine. The procedures were described and
approved by the Institutional Animal Care and Use Committee
(IACUC) at the Albert Einstein College of Medicine in animal
protocol number 20040707. APP-ki generation and genotyping
has been described [51]. Genotyping for the APP and APLP2 KO
alleles were performed as described in the Jackson Laboratory
WEB site.
Mouse brain preparations and GST pull-down
experiments
Brains were homogenized (w/v= 10 mg tissue/100 ml buffer)
in tissue homogenization buffer (20 mM Tris-base pH 7.4,
1 mM EDTA, 1 mM EGTA) supplemented with protease
and phosphatase inhibitors (PI and PhI). The post nuclear
supernatant (PNS) was prepared by precipitating the nuclei
and debris by centrifuging the homogenates at 1000 g for
10 min. GST fusion proteins were produced and purified as
described [38]. The binding experiments were performed using
,6 mg (200 pmol) of GST or GST-Mint1 PTB [47] following
the methods described previously [38]. To detect the bound
APP we used the 22C11 (Chemicon) antibody in Western blot
analysis.
Immunofluorescence staining
The muscle dissection, preparation, staining, and quantifica-
tion of the neuromuscular synapses have been previously
described [29,31]. Confocal images were obtained with a Zeiss
510 laser-scanning microscope, and quantification was done
using the ImageJ program from NIH. Antibodies: anti-
synaptophysin (Dako, 1:500); Anti-neurofilament (DSHB
1:500); anti-APP (Epitomics Inc., Y188, 1:250); anti-Alexa-
488/555/647 conjugated secondaries and a-bungarotoxin (Mo-
lecular Probe).
Statistical Analysis
Genotyping analysis of the offspring from APP
ki/2APLP2
+/2
male and female intercrosses was performed using x
2 analysis. The
Student’s t test was used for all other analyses (*P,0.05;
**P,0.01; ***P,0.001). Data were presented as the average 6
SEM.
Figure 1. Survival analysis of APP
TA ki mice on APLP2 null background. Analysis of genotypes of 128 offspring collected at P1 derived from
crosses of APP
TA/2APLP2
+/2 male and female mice. All genotypes were recovered at close to a Mendelian ratio (df=8, p.0.95). Analysis of genotypes
of these same offspring at P28 showed that the number of APP
2/2APLP2
2/2 animals observed was much lower than expected (highlighted in bold,
df=8, p,0.001). On the contrary, the number of APP
TA/TAAPLP2
2/2, APP
TA/2APLP2
2/2 was still close to a Mendelian ratio (B, df=8, p.0.20).
doi:10.1371/journal.pone.0018006.g001
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Expression of APP
TA on APLP2 null background does not
lead to early postnatal lethality
We testedwhether APLP2 KOmicecarrying the APP
TA mutation
havea lethal phenotype, similar to the APP/APLP2 dKO mice. This
genetic approach is ideal to assess whether the Thr
668 mediates the
essential functions of APP. We inter-crossed double heterozygous
miceharboringonealleleeachoftheAPPandAPLP2nullmutations
(APP
TA/2APLP2
+/2). We then determined the genotypes of the
offspringatpostnatalday1 (P1)andday 28(P28), and comparedthe
number observed against the number expected (Figure 1A and B).
Genotypingof P1 pups revealed a close to Mendelian distribution of
all genotypes, indicating no embryonic lethality as expected (Chi
square analysis: at P1, gd
2/e= 1.775, df=8, p.0.95). The
distribution of APP
TA/TAAPLP2
2/2 and APP
TA/2APLP2
2/2 mice
did not change between age P1 and P28 (Chi square analysis at P28,
gd
2/e= 10.575, df=8, p.0.20) (Figure 1). These results
demonstrate that mutation of Thr
668 into an Ala does not affect
the essential functions of APP that, when compromised, lead to
postnatal lethality of the APP/APLP2 double deficient mice. This is
in sharp contrast with what is observed in mice with deletion of the
entire APP intracellular domain or a point mutation of Tyr
682,
another conserved residues in the AID, which show early lethality
similarly to APP
2/2APLP2
2/2 animals [32,33].
Analysis of neuromuscular synapses development in
APP
TA knock-in animals
APP
2/2APLP2
2/2 animals show dramatic defects in the
development of NMJ [29,31]. This phenotype, just like the
postnatal early letality, requires the APP intracellular domain and
Tyr
682 [32,33]. Analysis of the neuromuscular synapse at P0 stage
showed that APP
TA/TAAPLP2
2/2 mutants exhibited normal
neuromuscular synapses, compared to APP
+/+APLP2
2/2 litter-
mate controls (Figs. 2A and 2C and quantified in 2B and 2D).
These results demonstrate that, in agreement with the survival
result, Thr
668 is not involved in the NMJ analysis of APP
TA/TA
APLP2
2/2 mutants revealed indistinguishable staining patterns
compared to the littermate APP
+/+APLP2
2/2 controls expressing
wild-type APP (Figure 2A and C).
The TA mutation does not affect the APP/Mint1
interaction
It has been proposed that presynaptic differentiation induced by
APP involves intracellular association with Cask and Mint1 [31],
Figure 2. No obvious neuromuscular synapse defects were observed in APP
TA/TA/APLP2
2/2 mice. A. Whole-mount staining of littermate
APP
+/+/APLP2
2/2control (Ctrl) and APP
TA/TA/APLP2
2/2 (TA) P0 diaphragm muscles with antibodies against synaptophysin (Syn). Anti-BTX was used to
mark the AchRs. B. Quantification of the average band width of endplates marked by anti-BTX (band width in control 260.0625.17 mm vs. TA
282.9618.63 mm. p.0.05, student t-test. Mean 6 SEM of 3 animals/genotype). C. Higher magnification images showing endplates closely apposed
by Syn and no axonal Syn staining in the TA mutant. D. Quantification of the area percentage of AchR endplates covered by Syn (control 0.62660.024
vs. TA 0.58860.017. p.0.05, student t-test. Mean6SEM of 20 endplates/genotype). Scale bar: A, 100 mm; C, 20 mm.
doi:10.1371/journal.pone.0018006.g002
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of synaptic adhesion proteins [53,54,55]. We asked whether
mutation of Thr
668 interfered with the formation of a Mint1/APP
complex. To test for this, we produced a recombinant protein in
vitro, in which the PTB domain of Mint1 was fused to GST for
production and purification from bacterial cultures. As a control
we produced GST on its own [47]. These recombinant proteins
were used for pull down experiments from mouse brain lysates.
GST-Mint1 interacts with APP in samples isolated from both WT
mice and mice expressing the APP
TA mutant form. The
interaction is specific since GST does not bring down APP and
a molecule reacting with the anti-APP antibody is not isolated by
GST-Mint1 when brain lysates from APP KO mice are used
(Fig. 3). These results support the view that the Thr
668 mutation
does not abolish presynaptic functions of APP because it does not
impair the recruitment of Mint1.
The highly conserved APP intracellular region is required for
APP-mediated survival and neuromuscular synapse assembly in
vivo, and Tyr
682 is necessary for these functions of APP [32,33]. We
report here that, in contrast, mutant APP mice with a non-
phosphorylatable alanyl residue at position 668, have preserved
essential APP functions. The non-consequential effects of the
mutation on Thr
668 suggest that the APP/Pin1 interaction does
not play a role in signaling pathways that regulate survival and
synaptogenesis.
Thr668 is followed by a Pro, which generates a consensus site
for phosphorylation, in APP family members and in other species,
except for APLP1 and Drosophila APP ortologue. Phosphorylation
of APP at Thr
668 impairs Fe65 interaction [47,56] while
promotes Pin1 binding [49]. Pin1 is a prolyl isomerase that
regulates protein function by accelerating conformational chang-
es. It has been reported that Pin1 is downregulated and/or
inhibited by oxidation in Alzheimer’s disease neurons [57].
Moreover, Pin1 knockout causes tauopathy and neurodegener-
ation [58], and increased amyloidogenic APP processing [50].
These findings have lead to propose that phosphorylation of
Thr
668 protects from AD by promoting interaction with Pin1,
which in turn has a protective effect against amyloidosis and
tauopathy. These conclusions however seem to be contradicted
by evidence showing that APP
TA knock-in mice, in which
phosphorylation at position 668 is suppressed, show levels of
Ab comparable to wild type mice, suggest that Thr
668
phosphorylation does not play an obvious role in governing the
physiological levels of brain Ab in vivo [51,52].
Theevolutionarypressurethat hasresultedinconservationofthis
residue during evolution of APP denotes the importance of Thr
668
for APP functions. However, the finding that the APP
TA mutation
rescues NMJ and lethality of APP/APLP2 deficient mice, argues
against an essentialfunctionforphosphorylationofthisresidue.The
synaptic promoting property of APP may involve the formation of
the APP/Mint1/Cask complex in pre-synaptic termini [31]. Mint1
belongs to a gene family that comprises also Mint3. Both Mint1 and
3 bind APP and have opposite effects on the localization of AID
[59]. Here we focused on Mint1 because only Mint1 interacts with
CASK. In the trans-synaptic interaction model we have previously
proposed for APP function in sysnaptogenesis,APP-Mint1-CASK is
likely the central complex mediating APP effect [31]. As discussed,
Mint1-CASK complex has also been implicated in Neurexin-
Neuroligin mediated signaling in presynaptic organization
[53,54,55]. The finding that Mint1 binds both WT and APP
TA
mutant but not APP
YG [51] backs this hypothesis.
Growing evidence supports a role for alteration of synaptic
function in AD. Our previous finding that the intracellular region
and Tyr
682 of APP plays a role in synaptogenesis makes it a
legitimate possibility that the APP intracellular domain may
contribute to AD pathogenesis [32,51]. If phosphorylation of
Thr
668 has a protective role in AD pathogenesis, the finding that
APP
TA/ALPL2
2/2 mice do not present NMJ development defects
represents a notable exception to this hypothesis. However, it is
still possible that Thr
668 and its phosphorylation may functionally
regulate synapses in the Central nervous system, especially those
involved in memory formation in the hippocampus. To answer
these questions, it will be important to unveil the biological
mechanisms that regulate phosphorylation of APP on Thr
668 and
the signaling pathways that are controlled by this functional
domain of APP. In addition, Thr
668 and its phosphorylation may
regulate signaling pathway that are distinct by those that when
compromised double mutant mice, lead to early lethality and NMJ
dysfunctions. It is also conceivable that those roles of Thr
668 may
play a pathogenic role in AD.
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